These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 20421698)

  • 41. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease.
    Güntert A; Campbell J; Saleem M; O'Brien DP; Thompson AJ; Byers HL; Ward MA; Lovestone S
    J Alzheimers Dis; 2010; 21(2):585-96. PubMed ID: 20571216
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease.
    Watt AD; Perez KA; Faux NG; Pike KE; Rowe CC; Bourgeat P; Salvado O; Masters CL; Villemagne VL; Barnham KJ
    J Alzheimers Dis; 2011; 24(1):47-59. PubMed ID: 21157020
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease.
    Pannee J; Törnqvist U; Westerlund A; Ingelsson M; Lannfelt L; Brinkmalm G; Persson R; Gobom J; Svensson J; Johansson P; Zetterberg H; Blennow K; Portelius E
    Neurosci Lett; 2014 Jun; 573():7-12. PubMed ID: 24796810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
    Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
    Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
    Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
    Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.
    Pesaresi M; Lovati C; Bertora P; Mailland E; Galimberti D; Scarpini E; Quadri P; Forloni G; Mariani C
    Neurobiol Aging; 2006 Jun; 27(6):904-5. PubMed ID: 16638622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
    Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
    Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology.
    Maddalena AS; Papassotiropoulos A; Gonzalez-Agosti C; Signorell A; Hegi T; Pasch T; Nitsch RM; Hock C
    Neurodegener Dis; 2004; 1(4-5):231-5. PubMed ID: 16908995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
    Lewczuk P; Kamrowski-Kruck H; Peters O; Heuser I; Jessen F; Popp J; Bürger K; Hampel H; Frölich L; Wolf S; Prinz B; Jahn H; Luckhaus Ch; Perneczky R; Hüll M; Schröder J; Kessler H; Pantel J; Gertz HJ; Klafki HW; Kölsch H; Reulbach U; Esselmann H; Maler JM; Bibl M; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2010 Feb; 15(2):138-45. PubMed ID: 18663368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
    Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease.
    Han Y; Jia J; Jia XF; Qin W; Wang S
    Neurosci Lett; 2012 May; 516(2):232-6. PubMed ID: 22503901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction of Alzheimer's disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions.
    Kitaguchi N; Kawaguchi K; Nakai S; Murakami K; Ito S; Hoshino H; Hori H; Ohashi A; Shimano Y; Suzuki N; Yuzawa Y; Mutoh T; Sugiyama S
    Blood Purif; 2011; 32(1):57-62. PubMed ID: 21346337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Higher activity of peripheral blood angiotensin-converting enzyme is associated with later-onset of Alzheimer's disease.
    Akatsu H; Ogawa N; Kanesaka T; Hori A; Yamamoto T; Matsukawa N; Michikawa M
    J Neurol Sci; 2011 Jan; 300(1-2):67-73. PubMed ID: 21040931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.